Korro Bio (NASDAQ:KRRO) Shares Down 4%

Korro Bio, Inc. (NASDAQ:KRRO) was down 4% during trading on Thursday . The company traded as low as $66.06 and last traded at $66.52. Approximately 14,025 shares traded hands during trading, a decline of 49% from the average daily volume of 27,381 shares. The stock had previously closed at $69.30.

Analysts Set New Price Targets

A number of research firms have weighed in on KRRO. HC Wainwright upped their price target on shares of Korro Bio from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Thursday, March 28th. BMO Capital Markets restated an “outperform” rating and set a $120.00 target price on shares of Korro Bio in a research note on Tuesday, March 26th. Piper Sandler reiterated an “overweight” rating and issued a $180.00 price target on shares of Korro Bio in a research note on Wednesday, March 27th. Finally, Royal Bank of Canada raised their price target on Korro Bio from $70.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, March 27th.

Korro Bio Trading Down 9.1 %

The firm’s 50-day moving average is $63.33. The company has a market cap of $505.02 million, a PE ratio of -0.74 and a beta of 2.18.

Institutional Trading of Korro Bio

Several hedge funds have recently bought and sold shares of KRRO. North Star Investment Management Corp. bought a new stake in Korro Bio during the fourth quarter worth approximately $48,000. Atlas Venture Life Science Advisors LLC bought a new stake in shares of Korro Bio in the 4th quarter worth about $53,648,000. Monashee Investment Management LLC bought a new stake in shares of Korro Bio in the 4th quarter worth about $4,352,000. Tower Research Capital LLC TRC bought a new stake in shares of Korro Bio in the 4th quarter worth about $190,000. Finally, Northern Trust Corp bought a new stake in shares of Korro Bio in the 4th quarter worth about $504,000. Hedge funds and other institutional investors own 13.18% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc is based in Cambridge, Massachusetts.